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Purpose: To test the toxicity and efﬁcacy of concomitant boost radiotherapy alone against concurrent
chemoradiation (conventional fractionation) in locally advanced oropharyngeal cancer in our patient
population.
Methods and materials: In this open-label, randomised trial, 216 patients with histologically proven Stage
III–IVA oropharyngeal cancer were randomly assigned between June 2006 and December 2010 to receive
either chemoradiation (CRT) to a dose of 66 Gy in 33 fractions over 6.5 weeks with concurrent cisplatin
(100 mg/m2 on days 1, 22 and 43) or accelerated radiotherapy with concomitant boost (CBRT) to a dose of
67.5 Gy in 40 fractions over 5 weeks. The compliance, toxicity and quality of life were investigated. Dis-
ease-free survival (DFS) and overall survival (OS) curves were estimated with the Kaplan–Meier method
and compared using log rank test.
Results: The compliance to radiotherapy was superior in concomitant boost with lesser treatment inter-
ruptions (p = 0.004). Expected acute toxicities were signiﬁcantly higher in CRT, except for grade 3/4
mucositis which was seen more in CBRT arm (39% and 55% in CRT and CBRT, respectively; p = 0.02). Late
toxicities like Grade 3 xerostomia were signiﬁcantly high in CRT arm than CBRT arm (33% versus 18%;
p < 0.0001). The quality of life was signiﬁcantly poor in CRT arm at all follow up visits (p < 0.0001). The
rates of 2 year disease-free survival were similar with 56% in the chemoradiotherapy group and 61% in
CBRT group (p = 0.2; HR-0.81, 95%CI-0.53–1.2). Subgroup analysis revealed that patients with nodal size
>2 cm had signiﬁcantly better DFS with CRT (p = 0.05; HR-1.59, 95%CI-0.93–2.7).
Conclusion: In selected patients of locally advanced oropharyngeal cancer, concomitant boost offers a
better compliance, toxicity proﬁle and quality of life with similar disease control, than chemoradiation.
 2013 Elsevier Ireland Ltd. Radiotherapy and Oncology 107 (2013) 317–324 Open access under CC BY-NC-NDConcurrent chemoradiotherapy (CRT) is a standard organ-
preservation approach for patients with locally advanced oropha-
ryngeal cancers (OPC) [1]. Robust and mature data from various
randomised studies and meta-analyses have favoured platinum
chemoradiation (CRT) typically with cisplatin dosed at 100 mg/
m2 every 3 weeks [2]. However, the toxicity associated with CRT
is frequently unsatisfactory [3,4] and is exaggerated in frail pa-
tients with poor nutritional reserve, which is a vital problem in
developing countries which contribute a major bulk of oropharyn-
geal cancers. However, a paucity of data exists regarding the out-
come of radiotherapy alone in this population; therefore apragmatic approach is to explore management options to reduce
long-term complications of intensive multi-modal therapy without
compromising disease control and survival.
Radiobiologically it is hypothesised that altered fractionation is
predicted to improve the therapeutic ratio through the differential
response between tumours and normal tissues. The two groups of
biologically sound fractionation regimen that have been exten-
sively studied are hyperfractionation and accelerated fractionation
[5]. Hyperfractionation stemmed from the observation of preferen-
tial sparing of late responding tissues relative to epithelial tissues
and some tumours as a result of decreasing the size of radiation
dose per fraction; and accelerated fractionation regimens emerged
through the recognition of the magnitude and hazard of tumour
clonogen proliferation during course of radiotherapy [6]. Results
of large randomised trials addressing the optimisation of radiation
fractionation collectively show that a number of biologically sound
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locoregional control rate and overall survival [5,7,8].
The university of Texas, M.D. Anderson Cancer Centre [9] has
introduced the novel concept of accelerated fractionation with
concomitant boost radiotherapy (CBRT) to counteract the effect
of accelerated repopulation in the latter half (>3 weeks) of radio-
therapy schedule. A similar CBRT schedule was introduced into
routine practice in our institute more than a decade ago and has
shown favourable results [10]. Although accelerated fractionation
induces more severe acute mucositis, the general observation is
that the late toxicity is not appreciably increased. Hence we
decided it would be interesting to compare treatment compliance,
toxicity (early and late), overall quality of life and oncological out-
come in concomitant boost radiotherapy (CBRT) versus concurrent
chemoradiation (CRT).
However, conducting clinical trials of non-inferiority in any dis-
ease with very low event rates is challenging [11] and to the best of
our knowledge, this is ﬁrst such study comparing CRT versus CBRT
in locally advanced oropharyngeal carcinoma in a randomised
setting.
Materials and methods
Study design (Fig. 1)
Patients
Between July 2006 and June 2010, two hundred and sixteen pa-
tients of histologically proven stage III–IV-A oropharyngeal carci-
noma were randomised using computer-generated procedure to
CRT and CBRT arm.
Patients had Karnofsky performance status >70 and adequate
haematologic (haemoglobin >10 gm/dl, absolute neutrophil count
>1500/ll, platelets >100,000/ll), hepatic and renal function (calcu-
lated creatinine clearance >60 mL/min). Exclusion criteria included
stage IV-B disease, previous treatment with RT or chemotherapy,
any prior or synchronous malignancy, hypersensitivity to platinum
agents and serious medical disease or pregnant state. Patients
whose lymph nodes were large enough or extending behind the
spinal cord, where it would be difﬁcult to spare the cord, were
not included in the study. The study was carried out only after
the protocol was approved by the institution’s ethics review board.
The study was registered in the central trial registration of India
(registration number-CTRI/2012/01/002369).
Radiation
All patients were simulated on Simulator CT (Phebus Mecaserto,
France) after immobilisation with a thermoplastic mould and trea-
ted with either Co-60 c-rays or 6 MV photons. The enlarged lymph
nodes were delineated by lead markers externally before simula-
tion. Patients were treated by parallelly opposed lateral portals in
both arms without any tissue compensators. Nodes were treated
electively in all patients. A parallel anterior lower neck ﬁeld was
used in selected patients. In the CRT arm, 40 Gy/20 fractions/
4 weeks was given to the primary and draining lymph nodes
(phase I) followed by 20 Gy/10 fractions/2 weeks after sparing
the spinal cord (phase II), and ﬁnal 6 Gy/3 fractions (phase III)
was delivered through additionally reduced portals with a margin
of 2 cm around the original gross tumour. In CBRT arm, dose of
45 Gy/25 fractions/5 weeks as phase I was given to the primary tu-
mour and the draining lymph nodes. After the completion of 10
fractions, the primary tumour and enlarged lymph nodes with a
margin of 1.5–2 cm, were boosted by a smaller ﬁeld i.e. ‘ﬁeld-with-
in-a ﬁeld’ (concomitant boost) as a second daily fraction, with a
minimum inter-fraction interval of 6 h, to dose of 22.5 Gy/15 frac-
tions/3 weeks as phase II to a total dose of 67.5 Gy/40 fractions/
5 weeks. Hence, electively irradiated regions received 45 Gy andgross tumour 67.5 Gy over a short time of 5 weeks. The biological
equivalent dose (BED) in both arms was calculated with the linear
quadratic model using the a/b value of 10 for tumour control prob-
ability in squamous cell cancers of the head and neck region and 3
for late reacting normal tissues. The BED for chemoradiation arm
was 79.2 Gy10 and 110 Gy3 while that of CBRT was 78.98 Gy10
and 105.75 Gy3 for tumour control and late reacting normal tissue
complication, respectively.
Chemotherapy
In the CRT arm, concurrent single agent cisplatin, 100 mg/m2
intravenously was administered on days 1, 22 and 43 of the radia-
tion schedule after proper hydration. RT was administered within
2 h after the cisplatin administration. A complete haemogram
and renal function tests were done before every cycle of cisplatin.
Chemotherapy was withheld in cases of any grade 2 or more
haematologic or renal toxicity, till the normal values were recov-
ered after speciﬁc management.
Acute and late treatment toxicities and follow up
Patients were monitored for mucosal and skin reactions at least
weekly during radiotherapy. Patients’ weight was also recorded
weekly to monitor nutritional status. Prophylactic antimycotics
were initiated in all patients during initial week of treatment.
The severity of acute toxicities was scored using the National Can-
cer Institute (NCI)-Common Terminology Criteria for Adverse
Events (CTCAE) scale [12].
The ﬁrst clinical follow up was scheduled at 6 weeks and there-
after every two months for the ﬁrst year and then quarterly. Up to
24 months, most patients underwent routine CT or MRI of head
and neck region at 6 monthly intervals. Chest X-rays were obtained
at 6 months intervals. All the patients were clinically examined in a
joint tumour board. Local control for the purpose of this analysis
was determined by clinical and radiological freedom from tumour
above the clavicles. Persistence of disease was considered as local
or regional failure from day zero. Fine needle aspiration cytology
or a biopsy was carried out to document a recurrence in clinically
suspicious cases.
Late toxicities were scored at each follow-up evaluation accord-
ing to CTCAE scale [12]. Detailed statistical analysis was performed
for patients with >12 months of complete toxicity data to study
differences in toxicity proﬁle between the two treatment arms.
Assessment of quality of life was done at randomisation, at
completion of treatment, 6 weeks and 6 months using University
of Washington Quality of life Questionnaire (UW-QOL) version
4.1 which is a pre-validated and accurate, and accepted interna-
tionally. The Indian patient population validation of the QOL ques-
tionnaire was also done and published in 2007, one year after we
embarked on this study [13,14].
Quality control
Two senior radiation oncologists in the department reviewed
the radiotherapy records of each randomised patient, including
their veriﬁcation ﬁlms (phase 1 and 2 portals), total dose and dose
per fraction as per the protocol. The documentation of acute and
late toxicities was also veriﬁed. All the patients on follow up were
clinically examined in a joint tumour board for response and tox-
icity assessment.
Statistical analysis
This trial was an open-label, randomised trial with 1:1 alloca-
tion ratio by means of permuted block randomisation method
using a computer generated in-house system. Frequency tables
with counts and percentages were used to describe pre-treatment
and treatment characteristics for each group. The categorical clin-
ical characteristics between the two treatments were compared
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median values were compared between the groups using the t-test.
The 2-year disease free survival was used as primary end point
because locoregional as well as distant failures after 2 years was
infrequent. Secondary endpoints included acute and late toxicities,
tumour response, quality of life and overall survival.
Actuarial disease free survival and overall survival rates were
calculated by the Kaplan–Meier method and stratiﬁed by stage
groups. The comparison between treatment arms were done using
log-rank test. Exploratory subgroup analysis was carried out on
various prognostic variables. Cox proportional hazard regression
was used to estimate the hazard ratios with 95% conﬁdence inter-
vals for disease-free survival for each arm. A p-value of <0.05 was
taken as signiﬁcant. Data were analysed using the statistical soft-
ware SPSS for windows (version 19.0).Results
Patient cohort and characteristics
Patients were well balanced between the two groups in terms of
age, sex, histology, stage distribution (Table 1).Treatment compliance
The mean tumour dose was 65.3 Gy and 67.1 Gy in chemoradi-
ation and concomitant boost arm, respectively. Patients who were
able to complete their treatment within the stipulated time plus a
3 day allowance for logistical problems and public holidays were
considered to have completed on time. Approximately 3% of CBRT
and 7% of CRT patients completed treatment P1 week treatment
break because of non-compliance and acute toxicities. The medianTable 1
Proﬁle of patients and radiotherapy details.
Gender CRT (n = 106)
No. of patients %
Male 101 95
Female 5 5
Age (years)
Mean/median 48.7/49
Range 32–65
T stage
T1 2 2
T2 15 14
T3 49 46
T4a 40 38
T4b 0 0
N stage
N0 16 15
N1 60 57
N2 30 28
N3 0 0
TNM Stage
III 50 47
IVA 56 53
Overall treatment time
Mean/median (days) 48 / 47.5
RT equipment
Co-60 84 79
6MV (linac) 22 21
Median ﬁeld size (cm2) (Avg. width  length)
Phase I 160 (10  16)
Phase II 103 (7  16) [off cord]
Phase III 52 (7  8) [boost]length of interruption was 11 days (CRT) and 4 days (CBRT)
(p = 0.004).
Compliance to chemotherapy was moderate, with 65% patients
completing three cycles of cisplatin. All except one patient, re-
ceived at least two cycles (200 mg/m2 cumulative dose). Most
common reason was inadequate haematologic, renal function
and severe asthenia. One patient developed severe (>90% blockade)
multiple arterial thrombosis involving descending aorta, common
iliac and femoral artery ﬁve days after the ﬁrst cycle chemotherapy
requiring vascular bypass graft .
Hospital admission and supportive care was required in 28 CRT
patients (28%) of at some point of their treatment, and in two pa-
tients of CBRT arm (p < 0.0001). Treatment related mortality i.e.
death during or within 1 month of treatment, was seen in 8 pa-
tients in CRT arm and none in CBRT.Acute toxicity
The acute toxicity rates conﬁrmed the excellent tolerance of the
concomitant boost regimen (Table 2A). Although grade 3 mucositis
occurred in 54% of CBRT patients, it did not cause any treatment
interruptions. There was signiﬁcantly higher incidence of severe
vomiting, asthenia and weight loss >10% in CRT patients. Predom-
inant chemotherapy induced toxicity were leucopenia, intractable
vomiting and deranged renal functions necessitating hospital
admission and appropriate management interventions. No grade
4 nephrotoxicity was observed. Treatment related mortality was
also higher in chemoradiation arm.Response to treatment and disease free survival
The response to treatment was assessed at 6 weeks after ther-
apy according to World Health Organization criteria for assessingCBRT (n = 110) p-Value
No. of patients %
103 94 0.9
7 6
–
52.6/52
35–68
2 2 0.09
26 24
51 46
31 28
0 0
36 33 0.05
46 42
28 26
0 0
61 56 0.2
49 45
36.4 / 36
85 77
25 23
160 (10  16)
54 (7  8) [C. boost]
–
Table 2
Distribution of (A) acute and (B) late toxicities according to CTCAE scale.
Toxicity Grade CRT (n = 106) CBRT (n = 110) p (v2)
N Valid%a N Valid%a
A. Acute toxicity
Mucositis 0 0 0 0 0 0.02
1 0 0 0 0
2 64 62 50 46
3 40 38 60 55
4 0 0 0 0
Dermatitis 0 0 0 0 0 0.06
1 18 17 2 2
2 54 52 21 19
3 28 27 67 61
4 4 4 20 18
Dysphagia 0 0 0 0 0 0.04
1 5 5 16 15
2 55 53 56 51
3 44 42 38 34
4 0 0 0 0
Vomiting 0 19 18 100 91 0.02
1 40 38 8 7
2 38 37 2 2
3 7 7 0 0
Dysguesia 0 0 0 0 0 0.5
1 0 0 2 2
2 104 100 108 98
Salivary changes 0 0 0 8 8 0.02
1 80 77 81 78
2 24 23 15 14
Weight loss 0 5 5 18 16 <0.0001
1 24 23 53 48
2 57 55 39 36
3 18 17 0 0
Asthenia 0 5 5 29 26 <0.0001
1 31 30 56 51
2 61 59 25 23
3 7 7 0 0
Pain 0 17 16 25 23 0.09
1 17 16 32 29
2 57 55 40 36
3 13 13 13 12
Haematotoxity 0 53 51
1 15 14
2 21 20
3 9 9
4 4 4
Renal dysfunction No 60 58
Yes 44 42
B. Late toxicity
Xerostomia 0 0 0 13 19 0.004
1 8 13 22 32
2 32 53 21 31
3 20 34 12 18
Persistent dysguesia 0 4 7 22 32 0.001
1 12 20 32 47
2 44 73 14 21
Dysphagia 0 42 70 63 39 0.04
1 12 20 3 39
2 2 33 1 18
3 4 7 1 4
Fistula 0 0 2 2
a Excluding missing values.
Table 3
Best tumour response at 6 weeks after treatment.
Response
group
Chemoradiation arm
(n = 106)a
Concomitant boost arm
(n = 110)
p Value
(v2)
Number (%) Number (%)
Complete
response
72 (68) 81 (74) 0.3
Partial
response
23 (22) 27 (25)
Progressive
disease
2 (2) 0
Unevaluable 2 (2) 2 (2)
v2, Chi square test.
a Seven patients (7%) in the CRT patients died before the ﬁrst evaluation.
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Table 3. Overall, the complete remission rate for locoregional dis-
ease was comparable (p = 0.3) between the treatment groups.
The disease free survival analysis was done on intention to treat
basis. The Kaplan–Meier estimate yielded 2 year disease free sur-
vival probabilities of 56% (CRT) and 61% (CBRT) (p = 0.2, hazard ra-
tio (HR)-0.81, 95% conﬁdence interval (CI)-0.53–1.2) (Fig. 2A). The
2-year overall survival was statistically equivalent among both the
arms (p = 0.17; HR-0.73, 95%CI-0.34–1.18).Attempt for salvage therapy
All recurrences were veriﬁed histologically, unless obvious by
clinical examination. In patients with residual tumour, disease
recurrence, or progression of disease, salvage surgery or palliative
treatment was offered, depending on the status of the individual
patient, their symptoms and previous treatment. Four patients
exhibited clinical evidence of persistent nodal disease with com-
plete remission of local disease 6 weeks after radiotherapy under-
went neck dissection. In the analysis of DFS, they were scored as
disease free.Effect of stage on locoregional tumour control
Although the study was not powered adequately for a subgroup
analysis, an exploratory subgroup analysis was undertaken to
identify criteria for patients who were more likely to beneﬁt from
the experimental arm. Univariate analysis was done for disease
stage group (III versus IVA) and T and N stages. Patients with stage
III disease beneﬁted most with CBRT (HR-0.63, 95%CI-0.31–1.2),
though patients with stage IV (HR-1.15, 95%CI-0.65–1.91) fared
better with chemoradiation (Fig. 3A and B, electronic supplement).
T stage did not affect the treatment outcome. One interesting ﬁnd-
ing in this study was that patients with nodal size greater that
2  2 cm (unilateral or bilateral), had signiﬁcantly poor DFS with
CBRT as compared to CRT (66% versus 35% CRT versus CBRT,
respectively, p = 0.05; HR-1.59, 95%CI-0.93–2.7) thus was the most
signiﬁcant predictor of poor response to CBRT [Fig. 2B].
Thus with these results we can interpret that concomitant boost
is an efﬁcient treatment option for locally advanced disease with
the maximum nodal size less than 2  2 cm, while chemoradiation
should be offered for all other patients with larger nodes.Late toxicity
Late toxicity data were based on minimum of 6 months of tox-
icity scoring. The characteristics of these patients were representa-
tive of the entire patient cohort. The late toxicity rates are
quantiﬁed in Table 2B. The most common toxicity was secondary
to impairment of salivary function, resulting in grade 3 xerostomia,
which was seen signiﬁcantly higher in CRT arm. Grade 4 skin reac-
tion in the form of ﬁstula was seen in two patients of CBRT group.
Osteoradionecrosis, laryngeal necrosis and myelopathy were not
observed.Quality of life
Quality of life (QOL) was assessed using the University of Wash-
ington-Quality of Life (UW-QOL) questionnaire. The QOL score post
treatment, 6 weeks and at 6 months was compared with the base-
line (pre-treatment) QOL score (Table 4 electronic supplement).
Fig. 1. Study design of the randomised trial.
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to the treatment or disease progression. The composite quality of
life score decreased after treatment in both arms, attributed by
the increased acute toxicities. But this difference in composite
QOL score was seen more in CRT arm, signifying patients having
signiﬁcantly poorer QOL immediately after treatment and at
6 weeks post treatment than for the CBRT arm (p < 0.0001 &
p < 0.0001, respectively). At 6 months, the CBRT patients has
reached their baseline QOL score as compared to CRT patients
who needed more time to repair the damage conceived during
the treatment (p = 0.001) (Fig. 4 electronic supplement).Discussion
To the best of our knowledge, this is the ﬁrst published random-
ised controlled study of non-inferiority comparing chemoradiation
with concomitant boost radiotherapy looking at acute/late toxicity,
health-related quality of life and loco-regional disease control in
locally advanced oropharyngeal cancers. Though our results did
not indicate any difference in loco-regional control, however, tox-
icity proﬁle (acute and late) and quality of life were signiﬁcantly
better in concomitant boost arm.Head and neck squamous cell carcinoma is the sixth most com-
mon cancer worldwide. The incidence of head neck cancers varies
widely around the world. Oropharyngeal cancer constitutes 3–5%
of the malignancies in Europe, while this ﬁgure in parts of South-
east Asia and India reaches up to 40–50% [15,16] contributing to
a major burden of disease. In contrast to the western population,
majority of Indian patients are frail and nutritionally deprived
and therefore are more likely to harbour treatment related morbid-
ity and mortality. Although multiple randomised trials [17,18] and
meta-analyses [2] have favoured concurrent platinum chemoradi-
ation in treatment of locally advanced head and neck cancers but at
the cost of increased toxicity which is over-exempliﬁed in these
frail patients, and therefore a signiﬁcant issue in developing coun-
tries [4]. Therefore a pragmatic approach is to evaluate alternative
and viable radiation schedules that provide superior response rates
and yet maintain favourable toxicity proﬁle.
By the time this trial was conceived there was enough evidence
to suggest the superiority of concomitant boost (CBRT) over con-
ventional fractionation especially for oropharyngeal cancers
[7,10,19,20]. The CBRT was designed to shorten overall length of
treatment thereby diminishing the opportunity for accelerated
repopulation of clogenic cells during therapy [6]. In oropharynx
cancers, a 10 day reduction in overall treatment time to around
(A)    Disease free survival by treatment group: 
No at risk
CRT 98 48 35 20 8 1 
CBRT 106 58 29 15 5 1 
(B)   Disease free survival by groups in lymph node size > 2 cm: 
No at risk       
CRT 62 26 18 13 5 1 
CBRT 35 12 7 5 2 1 
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Fig. 2. Disease free survival curve (Kaplan–Meier estimate). (A) The Kaplan–Meier curve shows the disease free survival is almost similar between the two treatment arms at
2 years (p = 0.231; log rank test). (B) The Kaplan–Meier curve shows that for tumour with lymph node size >2 cm have signiﬁcant better DFS with CRT as compared to CBRT.
(p = 0.054) CRT, chemoradiation; CBRT, accelerated fractionation with concomitant boost.
322 Chemoradiation versus concomitant boost radiotherapy in locally advanced oropharyngeal cancer5 weeks is estimated to yield a 10–15% improvement in local con-
trol [21]. The accelerated concomitant boost has gained use in
many centres because of convenience and radiobiological rationale
[10,22,23]. By limiting the volume of tissue exposed to accelerated
therapy, a reduction in overall treatment time on the order of1.5–2 weeks is possible without requiring reduction in the total
dose or the introduction of a treatment break. The RTOG 90–03
study had shown an improved disease free survival rates of
approximately 8% favouring hyperfractionation and accelerated
concomitant boost radiotherapy over standard fractionation with
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costly and labour intensive, the RTOG has recommended acceler-
ated concomitant boost RT as the new standard in this patient
population.
Although the present fractionation schedule was based on that
developed at University of Texas M.D. Anderson Cancer Centre, a
modiﬁed concomitant boost delivery is practised in our centre, in
which the 15 daily fractions of 1.5 Gy were given in a progressively
accelerated manner starting on day 10 of the basic treatment
(1.8 Gy/fraction). The schedule design was based on the notion that
the incremental dose required to compensate for tumour prolifer-
ation might increase progressively towards the end of treatment
[24,25].
In this study we observed signiﬁcantly poor treatment compli-
ance in chemoradiation group with higher treatment interruption,
hospital admissions and mortality, all attributed to the added tox-
icity due to chemotherapy, leading to poor quality of life and in-
creased treatment cost. The chemotherapy compliance was
moderate with 65% patients completing full three cycles of chemo-
therapy but all patients received at least two cycles of chemother-
apy. However, chemotherapy compliance was still superior to
some published data of chemotherapy compliance in literature
[26]. Compliance to chemotherapy was poorer probably due to rel-
atively poor nutritional reserve and frailty, leading to poor toler-
ance and increased chemotherapy related morbidity.
Drug toxicities were chieﬂy haematological, with an incidence
of 30% (grade 2/3/4). Severe nephro-toxicities were rare, though al-
tered renal function was seen in 40% of patients. One patient in the
CRT arm developed acute thrombosis of descending aorta ﬁve days
after the ﬁrst chemotherapy, which is an exceedingly rare but
potentially devastating complication of cisplatin, documented in
few case series [27].
Not unexpectedly, high rates of grade 3–4 acute mucosal reac-
tion were seen in CBRT arm, however, our results were consistent
with the values of 52–94% reported by other investigators [22,25].
In accelerated treatment, decreasing the duration of treatment
causes an increase in the rate of dose accumulation; thus acute
mucositis is expected to be enhanced. In contrast to our previous
observation with the similar RT technique, we observed greater
acute mucosal toxicity in this study, probably because in the previ-
ous study due to inclusion of other subsites (larynx and hypophar-
ynx), the boost ﬁeld volume was relatively smaller. Although the
mucositis was intense, it did not cause treatment interruption, this
was largely because the boost was sequenced during last phase of
treatment. Consequential late reaction caused by severe acute
mucositis was not seen. These results corroborated with earlier
publications by MacKenzie et al. [20] who showed superior out-
come with less morbidity by delayed concomitant boost. There
were signiﬁcantly higher incidences of severe vomiting, asthenia,
weight loss >10% and grade 3/4 dysphagia in chemoradiation arm.
Treatment relatedmortality i.e. death during or within 1 months
after treatmentwas seen in 8% of chemoradiation arm in contrast to
none in concomitant boost arm. High 30-day mortality with
chemoradiation has been reported in other phase II trial conducted
at a different academic teaching hospital in India, although different
in clinical design, it highlighted the risks of giving intensive
schedules without adequate support infrastructure [28].
Treatment response and the 2-year disease free survival were
similar between the groups. Exploratory subgroup analysis was
undertaken to identify patients who were more likely to beneﬁt
from the experimental arm. The efﬁcacy of concomitant boost RT
was more pronounced for stage III disease than for stage IV disease
where chemoradiation fared better. Thus stage III disease was
more likely to beneﬁt with concomitant boost. A further sub-
stratiﬁcation was done to see the difference in response among
the two arms based on T (tumour) and N (nodal) stages. Thisrevealed an interesting ﬁnding in the study. Though there was no
difference among the arms based on T stage, but patients with no-
dal size greater that 2  2 cm had signiﬁcantly poor disease free
survival with concomitant boost as compared to chemoradiation.
This selectively poor control at nodal target with accelerated
schedules in not unique and is well corroborated with earlier pub-
lications including the MARCH collaborative group meta-analysis,
which has shown that the effect of altered fractionation was signif-
icantly more pronounced on the primary tumour than on the nodal
disease [29]. The probable argument in favour of above mentioned
ﬁndings is that the stage III disease is more localised with small
nodes (N1) and is properly covered with adequate margins in the
boost ﬁeld, delivering tumouricidal dose of 67.5 Gy to gross dis-
ease. While the uninvolved neck on the other hand receives 45–
50 Gy which is sufﬁcient for sterilizing the subclinical microscopic
disease. But with a larger nodal disease there may be chances of
geographical miss while planning boost portal. Tumour is ade-
quately irradiated with adequate margins in both the arms, thus
not affecting the treatment outcome. Therefore, two major limita-
tions of CBRT technique in oropharyngeal cancers is that it is not
suitable for large nodal disease reaching up to posterior triangle
of neck, as it would hamper the spinal cord sparing by conven-
tional radiotherapy plus there will be chances of geographical miss.
Secondly, in patients with node/s in levels IV/V/VI would increase
the size of boost ﬁeld and thus markedly increase acute toxicity.
Though we cannot deduce a ﬁrm conclusion, however, this sub-
group analysis would help us to select patients appropriately both
for clinical practice and as well as in stratifying patients for design-
ing future studies using concomitant boost technique.
Late toxicity is a signiﬁcant issue when comparing new radio-
therapy regimen against the standard in head and neck cancers.
As exempliﬁed by the GORTEC and RTOG trial, concurrent chemo-
radiation is associated with higher late toxicity [4,30]. In our trial,
late toxicities in form of grade 2/3 xerostomia, dysphagia and grade
2 dysguesia were observed signiﬁcantly higher in the chemoradia-
tion arm (86%, 40% and 73%, respectively) as compared to concom-
itant boost. Therefore, by limiting the volume of tissue exposed to
accelerated therapy and because large fraction sizes are avoided
and inter-fraction intervals are maintained at more than 6 h, the
rate of serious late complication in concomitant boost arm re-
mained acceptable. Thus the results of CBRT have been consistent
with radiobiological predictors.
In contrast to most studies, we did not ﬁnd any advantage of
chemoradiation over concomitant boost. A possible explanation
could be that due to relatively poor nutritional reserve and frailty
of our patients, full scheduled course of three cycles of chemother-
apy was received by 65% of patients. Though there are data in lit-
erature suggesting that cumulative dose 200 mg/m2 is sufﬁcient
to yield beneﬁcial anti-tumour effect [31], and all our patient re-
ceived at least 2 cycles i.e. 200 mg/m2 of cisplatin. Furthermore,
CRT was complicated by poor compliance, greater toxicity and poor
quality of life. Secondly, low volume/risk disease subgroups, had
shown an excellent tumour control with the accelerated regimen,
which were at par with the control arm.
Another important advantage of concomitant boost schedule is
that it offers optimising the utilisation of available resources by
abbreviating the overall treatment time from 7 to 5 weeks which
is more so advantageous in settings where either facility are scarce
or places where the available facilities are clustered geographically
within a few regions [32]. Finally, the observed high 30-day mor-
tality with chemoradiation (8%) within monitored settings makes
a much stronger case to concentrate on relatively less intensive
yet beneﬁcial and pragmatic altered radiation-only fractionation
schedules.
Although we observed beneﬁts with concomitant boost in
terms of tumour control and a manageable toxicity proﬁle, the
324 Chemoradiation versus concomitant boost radiotherapy in locally advanced oropharyngeal cancerimplementation of altered fractionation schedules as a routine
practice is yet to be established. Strict selection of patients and
inherent inconvenience due to daily multiple fractions and a great-
er rate of acute reactions, particularly acute radiation mucositis
[7,19,33] and translating the beneﬁts of these fractionation sched-
ules to patients outside a clinical trial are yet to be assessed and
addressed. The follow-up of the present study was relatively short
and prevents us from commenting on the long term disease free
and overall survival. Further follow-up is warranted to highlight
the efﬁcacy of this regimen to bring forth the true essence. Another
limitation of the study is that this is much selected group, those pa-
tients requiring any posterior electron boost or with parapharyn-
geal extensions which may require complex planning were not
included in this study. Finally, HPV status of majority of patients
was unknown (who were accrued before 2010), since by the time
the trial was started, there was not enough evidence regarding
the importance of HPV positivity in these patients. Though most
of our patients had tobacco related cancer with >90% had history
of smoking or tobacco chewing, this still remains one of the major
limitations of this trial, as HPV has proven to have both prognostic
as well as predictive roles in oropharyngeal cancers. Nevertheless,
taking into consideration the social conditions, the nutritional sta-
tus of our population and the infrastructure, as highlighted in a few
of the recent studies from Asia [34], this study has brought forth
the importance of conducting such a trial and has shown that an
accelerated regimen is equally effective modality as chemoradia-
tion for locoregionally advanced oropharyngeal cancers in our
set-up.
Based on the results obtained, it is plausible that less morbid,
‘‘radiation only’’ concept like accelerated fraction with concomi-
tant boost may be appropriate for low-risk subgroups (stage III/
N0/N1) of locally advanced oropharyngeal cancers. However, the
efﬁcacy of RT only treatment with concomitant boost technique
compared with chemoradiation in these subgroups of patients
merits further study in appropriate large scale randomised study.
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